See more : Hail Cement Company (3001.SR) Income Statement Analysis – Financial Results
Complete financial analysis of Cadrenal Therapeutics, Inc. Common Stock (CVKD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cadrenal Therapeutics, Inc. Common Stock, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Tanabe Engineering Corporation (1828.T) Income Statement Analysis – Financial Results
- Ginkgo Bioworks Holdings, Inc. WT (DNA-WT) Income Statement Analysis – Financial Results
- Asahi India Glass Limited (ASAHIINDIA.NS) Income Statement Analysis – Financial Results
- BBB Foods Inc. (TBBB) Income Statement Analysis – Financial Results
- Sheng Siong Group Ltd (OV8.SI) Income Statement Analysis – Financial Results
Cadrenal Therapeutics, Inc. Common Stock (CVKD)
About Cadrenal Therapeutics, Inc. Common Stock
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | 0.00 | 0.00 |
| Cost of Revenue | 1.98K | 1.27K |
| Gross Profit | -1.98K | -1.27K |
| Gross Profit Ratio | 0.00% | 0.00% |
| Research & Development | 4.08M | 392.86K |
| General & Administrative | 3.55M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 |
| SG&A | 3.55M | 2.31M |
| Other Expenses | 0.00 | 0.00 |
| Operating Expenses | 7.63M | 2.70M |
| Cost & Expenses | 7.63M | 2.70M |
| Interest Income | 249.09K | 0.00 |
| Interest Expense | 17.10K | 107.11K |
| Depreciation & Amortization | 1.98K | 1.27K |
| EBITDA | -8.34M | -6.61M |
| EBITDA Ratio | 0.00% | 0.00% |
| Operating Income | -7.63M | -2.70M |
| Operating Income Ratio | 0.00% | 0.00% |
| Total Other Income/Expenses | -724.24K | -4.01M |
| Income Before Tax | -8.36M | -6.71M |
| Income Before Tax Ratio | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 4.00 |
| Net Income | -8.36M | -6.71M |
| Net Income Ratio | 0.00% | 0.00% |
| EPS | -9.63 | -8.66 |
| EPS Diluted | -9.63 | -8.66 |
| Weighted Avg Shares Out | 868.18K | 775.64K |
| Weighted Avg Shares Out (Dil) | 868.18K | 775.64K |
Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook
Recognized as innovative biopharma developing a potentially safer and superior anticoagulant for patients with implanted cardiac devices and rare cardiovascular conditions PONTE VEDRA, Fla. , Nov. 19, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company developing...
CADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS) MEDICAL CONGRESS
Leading heart failure specialist features tecarfarin data and Cadrenal's proposed clinical trial protocol at 8th EACTS Mechanical Circulatory Support Summit PONTE VEDRA, Fla. , Nov. 12, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a late-stage biopharmaceutical company developing tecarfarin,...
CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATE
PONTE VEDRA, Fla. , Nov. 7, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) (the "Company" or "Cadrenal"), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) designed to provide safer and superior anticoagulation for patients with...
Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds
PONTE VEDRA, Fla., Nov. 1, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., ("Cadrenal" or the "Company") (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) for certain rare medical conditions, today announced the entry into...
Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility
PONTE VEDRA, Fla. , Oct. 24, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) (the "Company" or "Cadrenal"), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) designed to offer safer, superior chronic anticoagulation for patients with...
CADRENAL THERAPEUTICS JOINS CORPORATE COUNCIL OF ANTICOAGULATION FORUM
Participation Reinforces Cadrenal's Commitment to Innovation, Education and Improved Patient Outcomes with Anticoagulation Therapy PONTE VEDRA, Fla. , Oct. 23, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA)...
Cadrenal Therapeutics to Participate in Lytham Partners Fall 2024 Investor Conference
PONTE VEDRA, Fla. , Sept. 23, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) designed to be a superior and safer chronic anticoagulant for warfarin-dependent patients with implanted...
Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD Patients
PONTE VEDRA, Fla. , Aug. 22, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, next-generation Vitamin K Antagonist (VKA) oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths...
Published Findings Highlight Tecarfarin's Potential and Reinforce Need for Better Anticoagulation Therapy in LVAD Patients
Analysis features the growing need to evolve anticoagulation therapy beyond warfarin to avoid gastrointestinal bleeding, a significant and common complication for left ventricular assist device (LVAD) patients resulting in expensive hospitalizations Tecarfarin, a novel vitamin K antagonist (VKA), uses a different...
Cadrenal Therapeutics to Present at Upcoming Investor Conferences
PONTE VEDRA, Fla. , Aug. 14, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, next-generation Vitamin K Antagonist (VKA) oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths...
Source: https://incomestatements.info
Category: Stock Reports